Replimune Group GAAP EPS of -$3.38 misses by $0.02

Replimune Group reported a GAAP EPS of -$3.38, missing estimates by $0.02. As of March 31, 2026, cash and short-term investments stood at $268.9 million, down from $483.8 million in the prior fiscal year due to operating cash burn for clinical development. The company expects existing funds to support operations through Q1 2027, covering commercialization scale-up for RP1 and general corporate needs.